QuantiFERON TB (QFT) was the first interferon gamma release assay (IGRA) utilizing whole blood stimulation as a test for TB infection, gaining FDA approval in 2001. Subsequently there have been ...

On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test has been used more than 100 million times to detect TB infection. QuantiFERON is an ...

QIAGEN QGEN recently unveiled its latest offering, the QuantiFERON-EBV RUO (Research Use Only) assay. This addition to the company’s existing QuantiFERON portfolio of tests marks a significant ...

The highly automated workflow on LIAISON ® platforms gives QuantiFERON ® customers a powerful, flexible automated option for all throughput ranges. The addition of the fully automated LIAISON ...

We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of ...

This patent, which is one of many held by QIAGEN protecting the QuantiFERON technology, covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection.

The patent, among several owned by QIAGEN that protect the QuantiFERON technology, encompasses significant innovations in the QuantiFERON-TB Gold Plus, which is employed worldwide for tuberculosis ...

(RTTNews) - QIAGEN (QGEN) and DiaSorin said Monday that the U.S. Food and Drug Administration has approved the LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS ...

This ruling underscores the strength of QIAGEN’s QuantiFERON intellectual property portfolio and protects the scientific advancements that have made QuantiFERON-TB Gold Plus the global standard ...

QIAstat-Dx and QuantiFERON test drive growth; EPS raised to $2.35 amid early margin target achievement. Get access to the leaderboards pointing to tomorrow’s biggest stock movers. Qiagen N.V ...